Sygnature Discovery

MARCH 7, 2023

Sygnature Discovery, the global integrated drug discovery company, has unveiled a new platform that facilitates the combinational high-throughput assembly and review of molecular degraders ( CHARMED ), in response to a sustained rise in demand for its multi-disciplinary expertise. What is the CHARMED platform?

Targeted Protein Degradation 52

Targeted Protein Degradation DNA Engineering Drugs 52

Broad Institute

FEBRUARY 27, 2024

CBTS Supergroup Meetings By Rose Circeo February 27, 2024 Breadcrumb Home Chembio-Therapeutics CBTS Supergroup Meetings Regular program meetings draw participants from many research communities to share cutting-edge research and brainstorm new project ideas in a wide variety of fields relevant to chemical biology and therapeutics science.

Targeted Protein Degradation 52

Targeted Protein Degradation DNA Engineering Science 52

Drug Target Review

OCTOBER 4, 2023

2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4 | ACS Chemical Biology.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

LifeSciVC

FEBRUARY 5, 2025

While the successful therapeutic targeting of transcription factors is a relatively new undertaking by industry, these proteins themselves are nothing new. One area of interest is that of oncology, where growing evidence has shown the role that transcription factors play in driving various cancers.

Small Molecule 67

Small Molecule Targeted Protein Degradation Regulations Disease 67